Income statement
USD
Annual
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | 0 | 0 | 0 | 0 | 0 |
| Operating Income | -16M | -18M | -15M | -27M | -28M |
| EBITDA | -17M | -17M | -15M | -26M | -28M |
| Net Income | -12M | -18M | -15M | -23M | -26M |
| EPS (Diluted) | — | — | — | — | — |
Healthcare
Live Price
Offline$1.16
+7.41% today
1Y Change
-29.03%
Window
Jun 23, 2025 → Jun 12, 2026
Coverage: 245 bars · Jun 23, 2025 → Jun 12, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Tiziana Life Sciences Ltd (TLSA) is a Healthcare stock with listed on NASDAQ. The stock last traded around $1.16 and down 29.0% across the available one-year price window (Jun 23, 2025 → Jun 12, 2026). Baseline metrics include revenue growth of 0.0%, EPS growth of +35.3%, a dividend yield of 0.0%. What stands out right now is revenue 0.0%, EPS +35.3%, free cash flow +90.1% with operating margin 0.0% and ROIC -41.2%. Stock Foundry combines TLSA price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
TLSA
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
TLSA Max Drawdown
-56.00%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for TLSA and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$0.0
FY Net Income
-$26.1M
-11.6% YoY
Free Cash Flow
-$8.8M
+45.8% YoY
Revenue Growth
+0.0%
EPS Growth
+35.3%
Gross Margin
0.0%
Net Margin
0.0%
Income statement
USD
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | 0 | 0 | 0 | 0 | 0 |
| Operating Income | -16M | -18M | -15M | -27M | -28M |
| EBITDA | -17M | -17M | -15M | -26M | -28M |
| Net Income | -12M | -18M | -15M | -23M | -26M |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
USD
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Cash & Equivalents | 4M | 1M | 18M | 42M | 66M |
| Total Assets | 11M | 12M | 26M | 49M | 71M |
| Total Liabilities | 7M | 7M | 7M | 8M | 8M |
| Shareholder Equity | 4M | 6M | 20M | 41M | 46M |
| Total Debt | 106K | 247K | 365K | 1M | 555K |
| Net Debt | -4M | -936K | -18M | -42M | -65M |
Cash flow positioning
Latest Full Year
Operating Cash Flow
9M
+45.7% YoY
Capital Expenditures
2K
+88.4% YoY
Free Cash Flow
9M
+45.8% YoY
Key ratios
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-125.8%
Debt / Equity
0.01x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.